Frontiers in Psychiatry (Jul 2018)
Assessment of Translocator Protein Density, as Marker of Neuroinflammation, in Major Depressive Disorder: A Pilot, Multicenter, Comparative, Controlled, Brain PET Study (INFLADEP Study)
- Antoine Yrondi,
- Bruno Aouizerate,
- Wissam El-Hage,
- Fanny Moliere,
- Claire Thalamas,
- Nicolas Delcourt,
- Marie Sporer,
- Simon Taib,
- Laurent Schmitt,
- Nicolas Arlicot,
- Nicolas Arlicot,
- Nicolas Arlicot,
- Deborah Meligne,
- Agnes Sommet,
- Agnes Sommet,
- Anne S. Salabert,
- Anne S. Salabert,
- Sebastien Guillaume,
- Sebastien Guillaume,
- Philippe Courtet,
- Philippe Courtet,
- Florence Galtier,
- Denis Mariano-Goulart,
- Denis Mariano-Goulart,
- Nicolas Menjot De Champfleur,
- Nicolas Menjot De Champfleur,
- Nicolas Menjot De Champfleur,
- Nicolas Menjot De Champfleur,
- Emmanuelle Le Bars,
- Emmanuelle Le Bars,
- Thomas Desmidt,
- Mathieu Lemaire,
- Vincent Camus,
- Maria J. Santiago-Ribeiro,
- Maria J. Santiago-Ribeiro,
- Maria J. Santiago-Ribeiro,
- Jean P. Cottier,
- Jean P. Cottier,
- Philippe Fernandez,
- Philippe Fernandez,
- Marie Meyer,
- Marie Meyer,
- Vincent Dousset,
- Olivier Doumy,
- Didier Delhaye,
- Lucile Capuron,
- Marion Leboyer,
- Marion Leboyer,
- Emmanuel Haffen,
- Patrice Péran,
- Pierre Payoux,
- Pierre Payoux,
- Christophe Arbus
Affiliations
- Antoine Yrondi
- Service de Psychiatrie et de Psychologie Médicale de l'Adulte, Centre Expert Dépression Résistante FondaMental, CHRU de Toulouse, Hôpital Purpan, ToNIC, Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, Toulouse, France
- Bruno Aouizerate
- Pôle de Psychiatrie Générale et Universitaire, Centre Expert Dépression Résistante FondaMental, CH Charles Perrens, UMR INRA 1286, NutriNeuro, Université de Bordeaux, Bordeaux, France
- Wissam El-Hage
- CHRU de Tours, Centre Expert Dépression Résistante FondaMental, Inserm U1253 iBrain, Inserm CIC 1415, Tours, France
- Fanny Moliere
- Department of Emergency Psychiatry and Postacute Care, Lapeyronie Hospital, CHU Montpellier, Expert Center for Resistant Depression, Fondation Fondamental, Montpellier, France
- Claire Thalamas
- CIC 1436, Service de Pharmacologie Clinique, CHU de Toulouse, INSERM, Université de Toulouse, UPS, Toulouse, France
- Nicolas Delcourt
- Centre Anti Poison CHU Toulouse Purpan, ToNIC, Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, Toulouse, France
- Marie Sporer
- Service de Psychiatrie et de Psychologie Médicale de l'Adulte, Centre Expert Dépression Résistante FondaMental, CHRU de Toulouse, Hôpital Purpan, Toulouse, France
- Simon Taib
- Service de Psychiatrie et de Psychologie Médicale de l'Adulte, Centre Expert Dépression Résistante FondaMental, CHRU de Toulouse, Hôpital Purpan, Toulouse, France
- Laurent Schmitt
- Service de Psychiatrie et de Psychologie Médicale de l'Adulte, Centre Expert Dépression Résistante FondaMental, CHRU de Toulouse, Hôpital Purpan, Toulouse, France
- Nicolas Arlicot
- CHRU de Tours, Unité de Radiopharmacie, Tours, France
- Nicolas Arlicot
- UMR 1253, iBrain, Université de Tours, Inserm, Tours, France
- Nicolas Arlicot
- 0INSERM CIC 1415, University Hospital, Tours, France
- Deborah Meligne
- 1Institut des handicaps des Handicaps Neurologiques, Psychiatriques et Sensoriels, FHU HoPeS, CHU Toulouse, France
- Agnes Sommet
- CIC 1436, Service de Pharmacologie Clinique, CHU de Toulouse, INSERM, Université de Toulouse, UPS, Toulouse, France
- Agnes Sommet
- 2Unité de Soutien Méthodologique à la Recherche Clinique (USMR), CHU de Toulouse, Toulouse, France
- Anne S. Salabert
- 3Departement de Médecine Nucléaire, CHU Toulouse, Toulouse, France
- Anne S. Salabert
- 4ToNIC, Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, Toulouse, France
- Sebastien Guillaume
- Department of Emergency Psychiatry and Postacute Care, Lapeyronie Hospital, CHU Montpellier, Expert Center for Resistant Depression, Fondation Fondamental, Montpellier, France
- Sebastien Guillaume
- 5INSERM U1061, Université de Montpellier, Montpellier, France
- Philippe Courtet
- Department of Emergency Psychiatry and Postacute Care, Lapeyronie Hospital, CHU Montpellier, Expert Center for Resistant Depression, Fondation Fondamental, Montpellier, France
- Philippe Courtet
- 5INSERM U1061, Université de Montpellier, Montpellier, France
- Florence Galtier
- 6Centre Hospitalier Régional Universitaire Montpellier, Montpellier, France
- Denis Mariano-Goulart
- 7PhyMedExp, Université de Montpellier, INSERM U1046, CNRS UMR 9214, Montpellier, France
- Denis Mariano-Goulart
- 8Département de Médecine Nucléaire, CHU de Montpellier, Montpellier, France
- Nicolas Menjot De Champfleur
- 9Département de Neuroradiologie, Hôpital Gui de Chauliac, Centre Hospitalier Régional Universitaire de Montpellier, Montpellier, France
- Nicolas Menjot De Champfleur
- 0Institut d'Imagerie Fonctionnelle Humaine, Hôpital Gui de Chauliac, Centre Hospitalier Régional Universitaire de Montpellier, Montpellier, France
- Nicolas Menjot De Champfleur
- 1Laboratoire Charles Coulomb, CNRS UMR 5221, Université de Montpellier, Montpellier, France
- Nicolas Menjot De Champfleur
- 2Département d'Imagerie Médicale, Centre Hospitalier Universitaire Caremeau, Nîmes, France
- Emmanuelle Le Bars
- 9Département de Neuroradiologie, Hôpital Gui de Chauliac, Centre Hospitalier Régional Universitaire de Montpellier, Montpellier, France
- Emmanuelle Le Bars
- 0Institut d'Imagerie Fonctionnelle Humaine, Hôpital Gui de Chauliac, Centre Hospitalier Régional Universitaire de Montpellier, Montpellier, France
- Thomas Desmidt
- 3CHRU de Tours, INSERM U1253, Université François Rabelais de Tours, Tours, France
- Mathieu Lemaire
- 3CHRU de Tours, INSERM U1253, Université François Rabelais de Tours, Tours, France
- Vincent Camus
- 3CHRU de Tours, INSERM U1253, Université François Rabelais de Tours, Tours, France
- Maria J. Santiago-Ribeiro
- UMR 1253, iBrain, Université de Tours, Inserm, Tours, France
- Maria J. Santiago-Ribeiro
- 0INSERM CIC 1415, University Hospital, Tours, France
- Maria J. Santiago-Ribeiro
- 4Service de Médecine Nucléaire, CHRU Tours, Tours, France
- Jean P. Cottier
- UMR 1253, iBrain, Université de Tours, Inserm, Tours, France
- Jean P. Cottier
- 5Service de Neuro radiologie, CHRU Tours, Tours, France
- Philippe Fernandez
- 6Departement de Médecine Nucléaire, Hopital Pellegrin, Bordeaux, France
- Philippe Fernandez
- 7Institut de Neurosciences Cognitives et Intégratives d'Aquitaine (UMR-5287), Université de Bordeaux, Bordeaux, France
- Marie Meyer
- 6Departement de Médecine Nucléaire, Hopital Pellegrin, Bordeaux, France
- Marie Meyer
- 7Institut de Neurosciences Cognitives et Intégratives d'Aquitaine (UMR-5287), Université de Bordeaux, Bordeaux, France
- Vincent Dousset
- 8CHU Bordeaux Neurocentre Magendie, INSERM U1215, Université de Bordeaux, Bordeaux, France
- Olivier Doumy
- Pôle de Psychiatrie Générale et Universitaire, Centre Expert Dépression Résistante FondaMental, CH Charles Perrens, UMR INRA 1286, NutriNeuro, Université de Bordeaux, Bordeaux, France
- Didier Delhaye
- 9Pôle de Psychiatrie Générale et Universitaire, Centre Expert Dépression Résistante FondaMental, CH Charles Perrens, Bordeaux, France
- Lucile Capuron
- 0INRA, Nutrition and Integrative Neurobiology (NutriNeuro), UMR 1286, University of Bordeaux, Bordeaux, France
- Marion Leboyer
- 1Pôle de Psychiatrie des Hôpitaux Universitaires, Centre Expert Dépression Résistante FondaMental, Hôpital Henri Mondor-Albert Chenevier, AP-HP, Créteil, France
- Marion Leboyer
- 2INSERM U955, Translational Psychiatry, Paris-Est University, Créteil, France
- Emmanuel Haffen
- 3Department of Clinical Psychiatry, Clinical Investigation Center 1431-INSERM, EA 481 Neurosciences, University of Bourgogne Franche-Comté, University Hospital of Besancon and FondaMental Foundation, Créteil, France
- Patrice Péran
- 4ToNIC, Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, Toulouse, France
- Pierre Payoux
- 3Departement de Médecine Nucléaire, CHU Toulouse, Toulouse, France
- Pierre Payoux
- 4ToNIC, Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, Toulouse, France
- Christophe Arbus
- Service de Psychiatrie et de Psychologie Médicale de l'Adulte, Centre Expert Dépression Résistante FondaMental, CHRU de Toulouse, Hôpital Purpan, ToNIC, Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, Toulouse, France
- DOI
- https://doi.org/10.3389/fpsyt.2018.00326
- Journal volume & issue
-
Vol. 9
Abstract
Background: Major depressive disorder (MDD) is a serious public health problem with high lifetime prevalence (4.4–20%) in the general population. The monoamine hypothesis is the most widespread etiological theory of MDD. Also, recent scientific data has emphasized the importance of immuno-inflammatory pathways in the pathophysiology of MDD. The lack of data on the magnitude of brain neuroinflammation in MDD is the main limitation of this inflammatory hypothesis. Our team has previously demonstrated the relevance of [18F] DPA-714 as a neuroinflammation biomarker in humans. We formulated the following hypotheses for the current study: (i) Neuroinflammation in MDD can be measured by [18F] DPA-714; (ii) its levels are associated with clinical severity; (iii) it is accompanied by anatomical and functional alterations within the frontal-subcortical circuits; (iv) it is a marker of treatment resistance.Methods: Depressed patients will be recruited throughout 4 centers (Bordeaux, Montpellier, Tours, and Toulouse) of the French network from 13 expert centers for resistant depression. The patient population will be divided into 3 groups: (i) experimental group—patients with current MDD (n = 20), (ii) remitted depressed group—patients in remission but still being treated (n = 20); and, (iii) control group without any history of MDD (n = 20). The primary objective will be to compare PET data (i.e., distribution pattern of neuroinflammation) between the currently depressed group and the control group. Secondary objectives will be to: (i) compare neuroinflammation across groups (currently depressed group vs. remitted depressed group vs. control group); (ii) correlate neuroinflammation with clinical severity across groups; (iii) correlate neuroinflammation with MRI parameters for structural and functional integrity across groups; (iv) correlate neuroinflammation and peripheral markers of inflammation across groups.Discussion: This study will assess the effects of antidepressants on neuroinflammation as well as its role in the treatment response. It will contribute to clarify the putative relationships between neuroinflammation quantified by brain neuroimaging techniques and peripheral markers of inflammation. Lastly, it is expected to open innovative and promising therapeutic perspectives based on anti-inflammatory strategies for the management of treatment-resistant forms of MDD commonly seen in clinical practice.Clinical trial registration (reference: NCT03314155): https://www.clinicaltrials.gov/ct2/show/NCT03314155?term=neuroinflammation&cond=depression&cntry=FR&rank=1
Keywords